5,618 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,618 shares of the company's stock, valued at approximately $390,000.

Several other institutional investors and hedge funds have also bought and sold shares of NVO. Center for Financial Planning Inc. lifted its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $33,000. Finally, CX Institutional purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately $36,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Stock Down 1.4%

NVO stock traded down $1.15 during trading on Friday, hitting $79.90. 7,465,072 shares of the stock traded hands, compared to its average volume of 7,025,619. The stock has a market cap of $358.57 billion, a price-to-earnings ratio of 24.29, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm's 50 day moving average is $67.30 and its two-hundred day moving average is $79.82. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.